Optimal management of metastatic renal cell carcinoma: an algorithm for treatment
- 9 June 2009
- journal article
- review article
- Published by Wiley in BJU International
- Vol. 104 (1) , 10-18
Abstract
The treatment of metastatic renal cell carcinoma (mRCC) has been changed by the introduction of targeted agents. Consideration of individual patient factors, such as previous treatment and prognostic risk, e.g. according to the Memorial Sloan‐Kettering Cancer Center (MSKCC) risk criteria), can assist in ensuring that patients receive appropriate targeted therapies. Available clinical evidence shows sunitinib to be the reference standard of care for the first‐line treatment of mRCC in patients at favourable or intermediate prognostic risk according to MSKCC criteria. Combined treatment with bevacizumab plus interferon‐α can also be considered for the first‐line treatment of mRCC in this setting. For the first‐line treatment of poor‐risk patients, temsirolimus has shown benefit in a phase III study, while sunitinib can also be considered. For second‐line treatment in cytokine‐refractory patients, sorafenib is recommended based on phase III trial results; sunitinib has also shown activity after failure of cytokine therapy or targeted agents. As well as antitumour activity, the tolerability of targeted agents should be evaluated in the context of individual patients, considering factors such as comorbidities and age. As our understanding of the activity of targeted agents for mRCC increases, we should ensure that these agents are used appropriately to provide patients with optimal treatment benefits.Keywords
This publication has 53 references indexed in Scilit:
- Toxicities Associated with the Administration of Sorafenib, Sunitinib, and Temsirolimus and Their Management in Patients with Metastatic Renal Cell CarcinomaEuropean Urology, 2008
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007
- Sunitinib Efficacy Against Advanced Renal Cell CarcinomaJournal of Urology, 2007
- Randomized Phase II Study of Erlotinib Combined With Bevacizumab Compared With Bevacizumab Alone in Metastatic Renal Cell CancerJournal of Clinical Oncology, 2007
- Clinical factors associated with outcome in patients with metastatic clear‐cell renal cell carcinoma treated with vascular endothelial growth factor‐targeted therapyCancer, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinomaAnnals of Oncology, 2006
- Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal CancerClinical Cancer Research, 2005
- Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal CancerJournal of Clinical Oncology, 2003